| |||||||||||||||
| Rating | Health Concerns |
|---|---|
![]() |
|
![]() |
Cerebellar ataxia (familial) Gingivitis (periodontal disease) Halitosis (if gum disease) Renal (kidney) failure |
![]() |
Chronic obstructive pulmonary disease (COPD) Insulin resistance syndrome (Syndrome X) Muscular dystrophy |
Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary
studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but
minimal or no scientific evidence. For a supplement, little scientific support and/or minimal
health benefit. | |
Deficiency is poorly understood, but it may be caused by synthesis problems in the body rather than an insufficiency in the diet. Low blood levels have been reported in people with heart failure, cardiomyopathy, gingivitis (inflammation of the gums), morbid obesity, hypertension, muscular dystrophy, diabetes, AIDS, and in some people on kidney dialysis. People with phenylketonuria (PKU) may be deficient in CoQ10 because of dietary restrictions.29 CoQ10 levels are also generally lower in older people. The test used to assess CoQ10 status is not routinely available from medical laboratories.
Some,30 but not all,31 research suggests that a fat-soluble form of CoQ10 is absorbed better than CoQ10 in granular (powder) form.32
Adult levels of supplementation are usually 30–90 mg per day, although people with specific health conditions may supplement with higher levels (with the involvement of a physician). Most of the research on heart conditions has used 90–150 mg of CoQ10 per day. People with cancer who consider taking much higher amounts should discuss this issue with a doctor before supplementing. There are several anecdotal reports of large amounts of CoQ10 resulting in improvements in certain types of cancer. However, controlled trials are needed to confirm these preliminary observations. Most doctors recommend that CoQ10 be taken with meals to improve absorption.
Congestive heart failure patients who are taking CoQ10 should not discontinue taking CoQ10 supplements unless under the supervision of a doctor.
An isolated test tube study reported that the anticancer effect of a certain cholesterol-lowering drug was blocked by addition of CoQ10.33 So far, experts in the field have put little stock in this report because its results have not yet been confirmed in animal, human, or even other test tube studies. The drug used in the test tube is not used to treat cancer, and preliminary information regarding the use of high amounts of CoQ10 in humans suggests the possibility of anticancer activity.34 35 36
Are there any drug
interactions?
Certain medicines may interact with coenzyme Q10. Refer to drug interactions for a list of those medicines.
1. Weber C, Jakobsen TS, Mortensen SA, et al. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. Int J Vitam Nutr Res 1994;64:311-5.
2. Thomas SR, Neuzil J, Stocker R. Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis? Mol Aspects Med 1997;18:S85-103.
3. Kelly GS. Sport nutrition: a review of selected nutritional supplements for endurance athletes. Altern Med Rev 1997;2:282-95.
4. Thorsteindottir B, Rafnsdottir S, Geirsson AJ, et al. No difference in ubiquinone concentration of muscles and blood in fibromyalgia patients and healthy controls. Clin Exp Rheumatol 1998;16:513-4.
5. Tanimura J. Studies on arginine in human semen. Part III. The influences of several drugs on male infertility. Bull Osaka Med School 1967;12:90-100.
6. Gaby AR. Coenzyme Q10. In A Textbook of Natural Medicine, by Pizzorno JE, Murray MT. Seattle: Bastyr University Press, 1998, V:CoQ10-1-8. [review].
7. Shigeta Y, Izumi K, Abe H. Effect of coenzyme Q7 treatment on blood sugar and ketone bodies of diabetics. J Vitaminol 1966;12:293-8.
8. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment of 3-hydroxy-3-methylglutaryl coenzyme I reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 1999;49:324-9.
9. Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drug Exptl Clin Res 1985;11:581-93.
10. Soja AM, Mortensen SA. Treatment of chronic cardiac insufficiency with coenzyme Q10, results of meta-analysis in controlled clinical trials. Ugeskr Laeger 1997;159:7302-8.
11. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig 1993;71:S134-6.
12. Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J 1992;13:1528-33.
13. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999;33:1549-52.
14. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000;132:636-40.
15. Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drug Exptl Clin Res 1985;11:581-93.
16. Gaby AR. The role of coenzyme Q10 in clinical medicine: part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. Altern Med Rev 1996;1:168-75 [review].
17. Fujioka T, Sakamoto Y, Mimura G. Clinical study of cardiac arrhythmias using a 24-hour continuous electrocardiographic recorder (5th report)—antiarrhythmic action of coenzyme Q10 in diabetics. Tohoku J Exp Med 1983;141(suppl):453-63.
18. Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985;56:247.
19. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Invesigt 1993;71:S116-23 [review].
20. Tanaka J, Tominaga R, Yoshitoshi M, et al. Coenzyme Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. Ann Thorac Surg 1982;33:145-51.
21. Folkers K, Wolaniuk J, Simonsen R, et al. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc Natl Acad Sci 1985;82:4513-6.
22. Imagawa M, Naruse S, Tsuji S, et al. Coenzyme Q10, iron, and vitamin B6 in genetically-confirmed Alzheimer’s disease. Lancet 1992;340:671 [letter].
23. Folkers K, Shizukuishi S, Takemura K, et al. Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res Commun Pathol Pharmacol 1982;38:335-8.
24. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995;212:172-7.
25. Digiesi V, Cantini F, Bisi G, et al. Mechanism of action of coenzyme Q10 in essential hypertension. Curr Ther Res 1992;51:668-72.
26. Gaby AR. The role of coenzyme Q10 in clinical medicine: part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. Altern Med Rev 1996;1:168-75 [review].
27. Singh RB, Khanna HK, Niaz MA. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role. J Nutr Environ Med 2000;10:281-8.
28. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541–50.
29. Artuch R, Vilaseca MA, Moreno J, et al. Decreased serum ubiquinone-10 concentrations in phenylketonuria. Am J Clin Nutr 1999;70:892–5.
30. Weiss M, Mortensen SA, Rassig MR, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Molec Aspects Med 1994;15:273–80.
31. Kaikkonen J, Nyyssonen K, Porkkala-Sarataho E, et al. Effect of oral coenzyme Q10 on the oxidation resistance of human VLDL + LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. Free Radic Biol Med 1997;22:1195–202.
32. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res 1998;68:109–13.
33. Larsson O. Effects of isoprenoids on growth of normal human mammary epithelial cells and breast cancer cells in vitro. Anticancer Res 1994;114:123–8.
34. Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994;199:1504–8.
35. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995;212:172–7.
36. Judy WV. Nutritional intervention in cancer prevention and treatment. American College for Advancement in Medicine Spring Conference, Ft. Lauderdale, FL. May 3, 1998.
| |||||||